Immunogenetic Diversity and Cancer Immunotherapy Disparities.
Cancer Discov
; 14(4): 585-588, 2024 Apr 04.
Article
em En
| MEDLINE
| ID: mdl-38571423
ABSTRACT
SUMMARY:
The success of checkpoint blockade cancer immunotherapies has unequivocally confirmed the critical role of T cells in cancer immunity and boosted the development of immunotherapeutic strategies targeting specific antigens on cancer cells. The vast immunogenetic diversity of human leukocyte antigen (HLA) class I alleles across populations is a key factor influencing the advancement of HLA class I-restricted therapies and related research and diagnostic tools.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunogenética
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Cancer Discov
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Holanda